Allon Therapeutics Inc. (TSX:NPC)

Chromos Molecular Systems Inc. (TSX:CHR)

Inimex Pharmaceuticals Inc.

MSI Methylation Sciences, Inc.

Neovasc Inc. (TSX-V:NVC)

Neuromed Pharmaceuticals Ltd.

Protox Therapeutics Inc. (TSX:PRX)

Urodynamix Technologies Ltd. (TSX-V:URO)

Allon Therapeutics Inc. (TSX:NPC) is a Canadian biotechnology company developing drugs that protect against neurodegenerative conditions such as Alzheimer’s disease, mild cognitive impairment, traumatic brain injury, stroke, multiple sclerosis and neuropathy. Allon’s drug discovery platform has resulted in the development of a unique class of peptide compounds that has demonstrated broad efficacy in numerous pre-clinical models of neurodegenerative diseases.

Chromos Molecular Systems Inc. (TSX:CHR) is a biotechnology company committed to the development and commercialization of innovative therapeutic products based on its two proprietary platforms: the Artificial Chromosome Expression (ACE) System and Rapid Expansion Method (REM). Chromos is using these unique approaches to develop immune – and gene-based cell therapies, and to engineer cell lines for biopharmaceutical production.

Inimex Pharmaceuticals Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), novel first in class drugs that selectively trigger the body’s innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease.

MSI Methylation Sciences, Inc. Methylation Sciences is a life science company, focused on reformulating and developing a widely used nutraceutical, with proven safety and efficacy in humans, as a new pharmaceutical for the treatment of depression. MSI is led by an experienced management team including Barry Guld and Nancy Harrison.

Neovasc Inc. (TSX-V:NVC) offers a suite of products to advance the treatment of heart and vascular disease. Neovasc designs technologies to offer improvements to current practice patterns -- in balloon angioplasty, stent insertion and related procedures, and vascular tissue repair.

Neuromed Pharmaceuticals Ltd. is a privately held biopharmaceutical company in business to develop safer and more effective pain drugs. Neuromed combines it pharmaceutical expertise in research, development and commercialization to improve existing pain treatments as well as develop new pain medicines.

Protox Therapeutics Inc. (TSX:PRX) is at the forefront of developing novel treatments in the emerging field of targeted toxin therapeutics for the treatment of cancer and other proliferative diseases. The company is actively developing two distinct but complementary platforms, INxin(TM) and PORxin(TM), in the development of therapeutic products for its clinical programs.

Urodynamix Technologies Ltd.

(TSX-V:URO) is a medical device company that develops and commercializes non-invasive medical devices based on proprietary applications of near-infrared spectroscopy (NIRS) for the diagnosis of urological diseases and conditions.